The Bipartisan Budget Act of 2018 (BBA 2018) directly affects Medicare Part D drugs, but its impact could expand beyond. Precision for Value’s Joanne Mai and Andrew Cournoyer cover how this change in the Medicare coverage gap program represents a small step toward encouraging biosimilar development, containing drug prices, and improving patient access.

To read the full article, please click here.